Bayer Aktiengesellschaft (FRA:BAYN)
Germany
· Delayed Price · Currency is EUR | Market Cap | 32.77B |
| Revenue (ttm) | 45.87B |
| Net Income (ttm) | -198.00M |
| Shares Out | n/a |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | 7.02 |
| Dividend | 0.11 (0.33%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 1,150,467 |
| Average Volume | 14,119 |
| Open | 33.75 |
| Previous Close | 33.58 |
| Day's Range | 33.25 - 33.92 |
| 52-Week Range | 18.60 - 34.91 |
| Beta | n/a |
| RSI | 69.91 |
| Earnings Date | Nov 12, 2025 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial StatementsNews
EQS-News: Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
EQS-News: IBM / Key word(s): Product Launch Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis 05.12.2025 / 09:05 CET/CEST The issuer is solely responsible for the co...
EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Bayer Aktiengesellschaft Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Euro...
Evotec & Bayer Launch Phase 2 Trial for Alport Syndrome Treatment
Bayer and Evotec are advancing a new hope for Alport syndrome, testing a targeted antibody in a rigorous Phase 2 trial to improve outcomes for young adults.
EQS-News: Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome
EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome 04.12.2025 / 08:30 CET/CEST The issuer is solely responsible f...
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A ...
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-base...
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigati...
Bayer (BAYRY) Achieves Milestone with Pediatric MRI Contrast Agent Study
Bayer (BAYRY) Achieves Milestone with Pediatric MRI Contrast Agent Study
Bayer releases data for contrast agent gadoquatrane in children
Bayer (BAYN) Stock Surges Following DOJ Support in Roundup Lawsuit
Bayer (BAYN) Stock Surges Following DOJ Support in Roundup Lawsuit
Bayer Welcomes Solicitor General Support In Supreme Court Review Of Roundup Case
(RTTNews) - Bayer (BAYN.DE) Tuesday said it is "pleased" by the U.S. Solicitor General's support for Supreme Court review of its petition in the Durnell case, calling the government's backing a signif...
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2206406924-0beb558aaa104bb1b9f43da1afcabb11.jpg)
Here's Why the Maker of Roundup Weed Killer's Stock Is Surging Today
Shares of Bayer are surging on their home exchange in Germany after the U.S. Solicitor General supported its efforts to have the Supreme Court review rulings on whether Roundup weed killer, produced b...
Bayer Starts New Phase III Study with Mirena for the Treatment of Nonatypical Endometrial Hyperplasia
Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena for the treatm...
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intraute...
Bayer (BAYRY) Gains as U.S. Backs Supreme Court Appeal on Roundup Cases
Bayer (BAYRY) Gains as U.S. Backs Supreme Court Appeal on Roundup Cases
Bayer surges after Trump administration backs Supreme Court review in Roundup case
Märkte heute: Bayer, Credo & MongoDB: Drei Stories, drei Rallys • news
In der heutige Sendung geht es um: Airbus, Bayer, Interactive Brokers, Spotify, Amazon, Synopsys, Shopify, Accenture, Credo Technology und MongoDB.
DAX Rises 0.8%; Bayer Shines
(RTTNews) - After opening marginally up, the German market's benchmark index DAX gained further ground in positive territory on Tuesday, led by strong buying momentum in agrochemical and pharmaceutica...
Morning movers: Trump Administration backs Bayer's Supreme Court bid
Bayer shares surge after the Trump administration urges the Supreme Court to take up the company's bid to limit thousands of lawsuits relating to claims its Roundup weedkiller causes cancer. Steve Sed...
Bayer Jumps After Trump Administration Backs Supreme Court Roundup Review
Lawsuits linking the weedkiller to cancer have dogged the German company since it bought Monsanto.
Bayer Crop Science Canada Launches EverGol Rise for Enhanced User Experience in Pulse Disease Control
CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science Canada announced the launch of EverGol® Rise, setting a new standard in pulse disease control. Combining four different active ingredients, EverGo...
Germany's Bayer sees shares pop as US government endorses legal appeal
The biotech giant is facing over 67,000 US lawsuits over allegations that its Roundup weedkiller causes cancer — a claim Bayer denies.
Markets Today: Euro Area Inflation Edges Higher, Gold Retreats Below $4200/oz. FTSE 100 Eyes Gains
A daily market briefing covering November 2025 Euro Area inflation (up to 2.2%), a retreat in gold prices, and mixed stock performance in Asia and Europe. The report notes Bayer's 15% surge, a steady ...
LBBW Discount-Zertifikate: Basiswert des Monats - Bayer • news
Bayer stock has its best day in 17 years after support from Trump’s solicitor general
Bayer shares rose as much as 15% on Tuesday after the U.S. solicitor general backed the company’s bid to get the Supreme Court to curtail litigation alleging its Roundup pesticide causes cancer.